MX2016017001A - Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine. - Google Patents

Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.

Info

Publication number
MX2016017001A
MX2016017001A MX2016017001A MX2016017001A MX2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A
Authority
MX
Mexico
Prior art keywords
acemetacin
predictive
acematacine
multiparticulated
release system
Prior art date
Application number
MX2016017001A
Other languages
Spanish (es)
Inventor
Romero Medina Silvia
Romero Castello Samuel
Parra Cervantes Patricia
Saul SOLORZA CAMACHO Karim
Soto Vazquez Ramon
Juarez Lopez Raul
Original Assignee
Productos Maver S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Maver S A De C V filed Critical Productos Maver S A De C V
Priority to MX2016017001A priority Critical patent/MX2016017001A/en
Publication of MX2016017001A publication Critical patent/MX2016017001A/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a stable pharmaceutical composition for oral administration comprising acemetacin. The acemetacin is framed into two granules, wherein a first granule is designed to release acemetacin immediately in a suitable dissolution medium and the second pellet is designed to provide a release of acemetacin in a predictive manner, wherein said granules are found in the same dosage unit which is a capsule. The stable pharmaceutical composition with acemetacin is useful for the treatment of disorders associated with inflammation and pain.
MX2016017001A 2016-12-19 2016-12-19 Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine. MX2016017001A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2016017001A MX2016017001A (en) 2016-12-19 2016-12-19 Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016017001A MX2016017001A (en) 2016-12-19 2016-12-19 Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.

Publications (1)

Publication Number Publication Date
MX2016017001A true MX2016017001A (en) 2017-10-06

Family

ID=60296206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017001A MX2016017001A (en) 2016-12-19 2016-12-19 Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.

Country Status (1)

Country Link
MX (1) MX2016017001A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199246A1 (en) * 2018-04-13 2019-10-17 Santa Farma İlaç Sanayi̇ A.Ş. A sustained release formulation comprising acemetacin with bimodal in vitro release

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199246A1 (en) * 2018-04-13 2019-10-17 Santa Farma İlaç Sanayi̇ A.Ş. A sustained release formulation comprising acemetacin with bimodal in vitro release

Similar Documents

Publication Publication Date Title
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
MX2018008021A (en) Methods and compositions for the treatment of seizure-related disorders.
MX2021016109A (en) Methods and compositions particularly for treatment of attention deficit disorder.
PH12015500823A1 (en) Modified release formulations for oprozomib
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201690974A1 (en) HYDROMORPHONE AND NALOXONE FOR THE TREATMENT OF PAIN AND OPIOID-INITIATED INTESTINAL DYSFUNCTION SYNDROME
MX2015012109A (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof.
HRP20161796T1 (en) Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patient which have been subjected to gastric bypass-surgery
EP3648745A4 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
MX2017005163A (en) Onapristone extended-release compositions and methods.
MX2016017001A (en) Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
SA516370446B1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX2018003890A (en) Pharmaceutical compositions containing a muscle relaxant and a non-steroidal anti-inflammatory drug (nsaid).
MX2017013643A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.
HRP20220701T1 (en) Fused benzazepines for treatment of tourette's syndrome
MX2017000384A (en) Capsule dosage form of metoprolol succinate.
WO2015166418A3 (en) Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient
MX2018011685A (en) Process for mesalazine solid formulations.
PH12016502540A1 (en) Pharmaceutical dosage forms
UA97982U (en) DRESSING MEDICINE FOR TABLETS
EA201650010A3 (en) PHARMACEUTICAL COMPOSITION ON THE BASIS OF 5-ETOXI-2- (2- (MORFOLINO) -ETHYLTIHO) BENZIMIDAZOLE DIHYDROCHLORIDE AND / OR BASIS
IN2013MU03069A (en)